Piperidine-based peroxisome proliferator-activated receptor-a agonists are agents that are efficacious in improving lipid, glycemic, and inflammatory indicators in diabetes and obesity. This study sought to determine whether CP-900691 ((S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP), a member of this novel class of agents, by decreasing plasma triglycerides, could prevent diabetic nephropathy in the Black and Tan, BRachyuric (BTBR) ob/ob mouse model of type 2 diabetes mellitus. Four-week old female BTBR WT and BTBR ob/ob mice received either regular chow or one containing CP (3 mg/kg per day) for 14 weeks. CP elevated plasma high-density lipoprotein, albuminuria, and urinary excretion of 8-epi PGF 2a , a product of the nonenzymatic metabolism of arachidonic acid and whose production is elevated in oxidative stress, in BTBR WT mice. In BTBR ob/ob mice, CP reduced plasma triglycerides and non-esterified fatty acids, fasting blood glucose, body weight, and plasma interleukin-6, while concomitantly improving insulin resistance. Despite these beneficial metabolic effects, CP had no effect on elevated plasma insulin, 8-epi PGF 2a excretion, and albuminuria, and surprisingly, did not ameliorate the development of diabetic nephropathy, having no effect on the accumulation of renal macrophages, glomerular hypertrophy, and increased mesangial matrix expansion. In addition, CP did not increase plasma high-density lipoprotein in BTBR ob/ob mice, while paradoxically increasing total cholesterol levels. These findings indicate that 8-epi PGF 2a , possibly along with hyperinsulinemia and inflammatory and dysfunctional lipoproteins, is integral to the development of diabetic nephropathy and should be considered as a potential target of therapy in the treatment of diabetic nephropathy.
Diabetes is characterized by chronic hyperglycemia and dyslipidemia, with the development of diabetes-specific complications in nerves, retina, kidney and other organs. Diabetic nephropathy (DN), one of major complications of diabetes mellitus, is the most common cause of end-stage renal disease in the United States and Europe. 1 Approximately one-third of people with diabetes develop evidence of nephropathy, eventually constituting over half of those on dialysis. While progressive DN is most likely due to a combination of environmental and genetic influences, the exact pathophysiologic mechanisms remain to be elucidated. The onset and course of DN can be ameliorated in some patients by several interventions (ie, changes in lifestyle, glycemic control, and renin-angiotensin-aldosterone system (RAAS) inhibition). However, mortality and morbidity due to DN is increasing, 2 making the development of more effective interventions a compelling task. Numerous studies suggest that hyperlipidemia is an independent risk factor in the development of DN 3 and that elevated levels of plasma lipids have been associated in the progression of renal dysfunction. 3, 4 Peroxisome proliferator-activated receptors (PPARs) are members of a family of ligand-activated transcription factors, consisting of three members (a, g, and b/d). 5 The insulinsensitizing thiazolidinedione (TZD) class of PPARg ligands have well-established efficacy in the treatment of type 2 diabetes mellitus (T2DM), 6 and PPARa ligands such as the fibrate class of oral hypolipidemics (ie, fenofibrate) increase plasma high-density lipoprotein-cholesterol (HDL-C) and decrease plasma triglycerides (TGs) in people with hyperlipidemia. 7 However, TZDs, despite ameliorating DN in animal models of diabetes and in people with T2DM, 8, 9 are no more effective than other oral antidiabetics (ie, metformin) in this regard 10 and their cardiovascular side effects (increased risk of congestive heart failure and myocardial infarction) make the use of these drugs in the treatment of DN a challenge. PPARa is mainly expressed in tissues with high rates of fatty acid metabolism, regulating the expression of genes that promote fatty acid synthesis and oxidation. PPARa ligands are observed to have a variety of beneficial effects in animal models of DN, 11 and data from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) and ACCORD (Action to Control Cardiovascular Risk in Diabetes) studies, both randomized, controlled clinical trials investigating the benefits of fenofibrate in preventing cardiovascular complications in people with type 2 diabetes, showed a reduction in rates of progression to albuminuria, indicating a therapeutic potential for such agents in the treatment of DN. 12, 13 A major limitation in elucidating mechanisms underlying DN has been the lack of relevant animal models, with most models developing some, but not all, features of DN. [14] [15] [16] We have characterized DN in the Black and Tan, BRachyuric mouse with the leptin deficiency mutation (BTBR ob/ob), possessing many features of advanced human DN. 17 Use of this preclinical model allows us to test the mechanisms of altered disease pathophysiology and efficacy of specific interventions.
The purpose of the present study was to determine whether CP-900691 ((S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP), a novel, potent, and selective PPARa agonist, [18] [19] [20] by primarily decreasing plasma TGs, can prevent the development of DN. CP decreased body weight (BW) and plasma TGs and had pronounced hypoglycemic and anti-inflammatory effects, while upregulating fatty acid oxidation gene expression in BTBR WT and BTBR ob/ob mice. Treatment with CP increased total cholesterol in BTBR ob/ob mice, without having any effect on HDL-C, and surprisingly, did not prevent DN, having no effect on plasma insulin levels, urinary excretion of 8-epi PGF 2a (8-epi) , and mesangial matrix expansion or macrophage accumulation. These results suggest that increases in renal 8-epi, associated with hyperinsulinemia and altered lipoproteins, contribute to DN.
MATERIALS AND METHODS Animals
The Institutional Animal Care and Use Committee of the University of Washington in Seattle approved all experimental protocols and procedures. The establishment and care of BTBR ob/ob mice has been described previously. 17 We placed 4-week-old female, BTBR wild-type (BTBR WT, n ¼ 9) and BTBR ob/ob (BTBR ob/ob, n ¼ 9) mice on standard rodent diet (Bio-Serv, Frenchtown, NJ, USA), an age where there were no observable changes in albumin-creatinine ratio, 17 and no alterations in renal structure were observed (unpublished observation). This early age for starting treatment also reflects our unpublished experience that by 6 weeks of age some BTBR ob/ob mice will have albuminuria. CP (3 mg/kg per day; Pfizer, Groton, CT, USA) was incorporated into the diet and administered ad libitum. The mice were treated for 14 weeks, for a total of 18 weeks of age, an age where the maximum renal damage was observed. 17 In selecting a dose for evaluating the actions of CP in BTBR WT and BTBR ob/ob mice, we chose to study the administration of 3 mg/kg per day, a dose shown to be approximately 100 Â more selective for PPARa than fibric acid derivatives and where the maximum hypotriglyceridemic effect was observed, both in studies describing piperidine-derived compounds in mice 19 and reinforced by a studies using CP in other species. 20 Mice were fasted for 6 h before drawing of blood on the day of killing. After euthanasia, the internal organs and the subcutaneous, retroperitoneal, epididymal, and subscapular adipose tissues were excised and weighed. Portions were either snap frozen with liquid N 2 or fixed with 10% neutral-buffered formalin and embedded in paraffin wax. Frozen tissues were stored at À 70 1C until use. BWs were measured weekly and lean BW was calculated as the weight of mice after removal of all internal organs and adipose tissues. In addition, tibias were removed, cleaned, and measured.
Blood Chemistry and Insulin Tolerance Tests
Serum cholesterol, TGs, non-esterified fatty acids (NEFAs), insulin, adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a) were analyzed at the University of Washington Mouse Metabolic Phenotyping Center (MMPC) metabolic testing core. Insulin, adiponectin, IL-6, and TNF-a was measured via the Luminex Platform. HDL-C was measured indirectly by polyethylene glycol precipitation of non-HDL and measurement of total cholesterol levels in the supernatant. In rodents, PPARa agonists have hepatic and muscular side effects. 21 Increases in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatine kinase (CK) activity ( Table 2) were associated with both DM and CP treatment, but no fibrosis or hepatocellular carcinomas were observed (data not shown). ALT and AST activity were measured using the ALT (SGPT) Liquid and AST (SGOT) Liquid kits (Pointe Scientific, Canton, MI, USA). CK was determined via the Stanbio CK, Liqui-UV (NAC) kit (Stanbio Labs, Boerne, TX, USA) according to the manufacturer's instructions.
Blood glucose was monitored bi-weekly using the Freestyle Blood Glucose Monitor (Abbott Diabetes Care, Alameda, CA, USA), beginning at 4 weeks. Insulin sensitivity was assessed 1 week before the end of the study in treated and untreated BTBR ob/ob mice using insulin tolerance tests (ITTs), performed after a 4-h fast by an intraperitoneal (IP) injection of diluted insulin (Humulin, 10 IU/g BW). IP insulin (1 IU/g BW), a dose that effectively decreases fasting blood glucose in WT mice, was without effect in the BTBR ob/ob (unpublished observations). Blood was drawn via the saphenous vein at 0, 15, 30, 60, and 120 min after injection for blood glucose measurements.
Urinary Analysis
Urine was collected from individual mice 6 h before killing. Urinary albumin and creatinine were analyzed as described previously 17 and extrapolated to obtain a 24-h rate. 8-Epi and 8-hydroxy 2-deoxy-guanosine (8OH-dG) were measured using their respective ELISA kits (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's instructions.
Immunohistochemical Analysis
Kidneys and other organs were obtained from WT and BTBR ob/ob mice after 14 weeks of drug therapy. Tissue sections were fixed, embedded, immunostained, and analyzed as described previously, 17 as were glomerular mesangial expansion and matrix accumulation. Briefly, the mesangial area occupied by silver methenamine-stained matrix was quantified, as was the total area positive for matrix, by computer image analysis (Image Pro Plus; Media Cybernetics, Rockville, MD, USA), for each glomerular crosssection. Mesangiolysis was determined by assessing the silver methenamine-stained glomeruli and scoring at least 50 glomeruli per section, scored present when lucency and dissolution of the normally compact silver-staining mesangial matrix was present and/or there were dilatation/ballooning of adjacent capillary loops.
Rat anti-Mac-2 (1:5000; Cedarlane, Hornby, Ontario, Canada) and rabbit polyclonal anti-p57 (1:3000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used to visualize glomerular macrophages and podocytes, as published previously. 18 Quantification for Mac-2 and p57 were performed on digital images of immunostained tissues by counting, in a blinded manner, the number of Mac-2-positive cells and p57positive podocytes per glomerular cross-section in 50 glomeruli, per animal.
Gene Expression Analysis
Total RNA was extracted from sections of frozen tissues using the SV Total RNA Isolation minikit (Promega, Madison, WI, USA), treated with DNase (DNase I, 15 min at 25 1C) to eliminate contamination of genomic DNA and quantified via UV spectrophotometry (NanoDrop 3300; Thermo Scientific, Wilmington, DE, USA). cDNA was then synthesized from RNA (500 ng), using the RevertAidt First Strand cDNA kit (Fermentas, Glen Burnie, MD, USA). Primer sequences for target genes were identified using PrimerBank and RTPri-merDB databases ( Supplementary Table 1 ) and purchased from Invitrogen (Carlsbad, CA, USA). Reverse transcription quantitative real-time polymerase chain reaction was performed using Brilliant s SYBR s Green qPCR Master Mix (Strategene, Santa Clara, CA, USA) and analyzed using the DNA Engine Opticon s 2 System (Bio-Rad, Hercules, CA, USA). Samples were analyzed in duplicate and normalized using 18S ribosomal subunit as reference gene. Relative mRNA expression was expressed using the DD cycle threshold (Ct) method. For the analysis of random mutation, renal cortical tissues were digested for 1 h in a buffer containing 0.2 mg/ml proteinase K (Sigma-Aldrich, St Louis, MO, USA), 0.75% SDS, 0.01 M Tris-HCl, 0.15 M NaCl, and 0.005 M EDTA (pH 7.8). Total DNA was extracted using phenolchloroform (1:1) followed by ethanol precipitation. DNA was then diluted and digested in a specialized TaqaI buffer in the presence of 100 U TaqaI (NEB, Ipswich, MA, USA) and 1 Â BSA for 10 h, with the addition of 100 U of TaqaI per hour. Random mutation was detected via qPCR, performed using a DNA Engine Opticon s 2 System. Amplicons were visualized with Brilliant s SYBR s Green qPCR Master Mix. Primers used for amplification are listed in Supplementary Table 1 . qPCR was performed in 25 ml reactions containing 2 Â Brilliant SYBR Green qPCR Master Mix, 20 pmol forward and reverse primers, and 2 U uracil DNA glycosylase (UDG). The samples were amplified as follows: UDG incubation at 37 1C for 10 min, 95 1C for 10 min, followed by 45 cycles of 95 1C for 0.5 min, 60 1C for 1 min, and 72 1C for 1.5 min. Samples were held at 72 1C for 5 min and immediately stored at À 20 1C.
Statistical Analysis
All values are expressed as the mean ± s.e.m. and analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA). Po0.05 was considered as statistically significant.
RESULTS

Body and Tissue Weights
To evaluate changes in growth and BW, we analyzed 4-weekold BTBR WT and BTBR ob/ob mice treated with CP for 14 weeks (Figure 1a ). Both total and lean BWs were increased in BTBR ob/ob mice over the 14 weeks ( Figure 1b , Table 1 ), an increase that was attenuated by CP treatment. We measured tibia lengths (TLs) as an index of growth. TLs were attenuated in BTBR ob/ob mice, and CP treatment caused a further decrease in both BTBR WT and BTBR ob/ob mice (Table 1) .
Overall, tissue weights were increased in BTBR ob/ob compared with BTBR WT mice. CP treatment induced hepatomegaly in both groups, similar to the effects of other PPARa agonists in rodents. 21 Despite the increase in size and concomitant increase in plasma ALT/AST, histochemical analysis of hemotoxylin-and eosin-stained livers demonstrated no obvious or significant injury (unpublished observations). Elevated kidney weights in the BTBR ob/ob mice were decreased with CP (Table 1) . However, while CP treatment reduced adipose tissue weights in BTBR WT mice, it had no effect on epididymal, retroperitoneal, and subscapular adipose tissues in the BTBR ob/ob mice.
Blood Glucose and Insulin Resistance
To see whether CP-induced decreases in BW had any effect on diabetes and insulin resistance (IR), we analyzed fasting blood glucose and insulin tolerance. BTBR ob/ob mice were hyperglycemic and insulin resistant, as reported previously 17, 22 (Figure 2a and Table 2 ). In BTBR WT mice, CP decreased plasma insulin levels and had a modest hypoglycemic effect. In the BTBR ob/ob, CP attenuated hyperglycemia (Figure 2a ), without having any effect on plasma insulin ( Table 2) . To evaluate the effect of CP on IR, ITTs were performed in BTBR ob/ob mice. In untreated BTBR ob/ob mice, insulin administration was without effect, whereas in CP-treated mice, insulin decreased blood glucose ( Figure 2b ). Analysis of the areas under the curve of blood glucose demonstrated significant improvement of IR ( Figure 2c ).
Serum Lipids and Blood Chemistry
CP and other piperidine-derived PPARa agonists have demonstrated potent hypolipidemic and anti-inflammatory effects in rodents and other species. 20, 21 To verify the efficacy of our treatment regimen, we measured serum lipids and indicators of systemic inflammation. BTBR ob/ob mice are hyperlipidemic, with elevated serum TG, NEFA, and total cholesterol levels. In BTBR WT mice, CP treatment increased HDL-C, lowered serum TG, but not NEFA levels ( Table 2 ). In the BTBR ob/ob mice, CP treatment decreased serum TG and NEFA without having any effect on HDL-C while concomitantly increasing total cholesterol levels ( Table 2 ).
PPARa agonists have been shown to be mildly hepatotoxic and myopathic when administered to rodents. 22 We therefore analyzed plasma ALT, AST, and CK levels in BTBR WT and BTBR ob/ob mice. CP induced increases in ALT and AST CP treatment increased adiponectin levels in WT mice, without having any effects on IL-6 and TNF-a. BTBR ob/ob mice had lower adiponectin and higher IL-6 levels, indicating a systemic inflammation. Treatment with CP lowered IL-6, while having no effect on serum adiponectin. TNF-a values in BTBR ob/ob mice were below the limits of detection of the assay ( Table 2) .
Hepatic Gene Expression
Previous studies have shown PPARa as a key regulator of the expression of hepatic genes associated with mitochondrial and peroxisomal b-oxidation. 5 In mice, CP-related piperidine compounds robustly induce canonical pathways involved in lipid metabolism. 20 We therefore analyzed hepatic RNA isolated from CP-treated and -untreated BTBR WT and BTBR ob/ob mice and quantified the expression of several of these PPARa-dependent genes. Mitochondrial and peroxisomal b-oxidation-associated genes, namely isoforms of carnitine palmitoyl acyltransferase (cpt1a, cpt1b, and cpt2) and palmitoyl acyl CoA oxidase-1 (acox1), were increased in livers of BTBR ob/ob mice (Figures 3a-f ). These changes were associated with increases in PPAR-g (pparg) expression but not PPAR-a (ppara) expression (Figures 3g-h) . In BTBR WT mice, CP treatment had no effect on cpt1a, while increasing acox1, cpt1b, and cpt2 expression. CP treatment in the BTBR ob/ob mice potentiated acox1, cpt1b, and cpt2 expression, while attenuating the increases in pparg.
Urinary Parameters
To assess the efficacy of CP on DN, we analyzed urinary albumin, creatinine, glucose, and 8-epi excretion in CP-treated and -untreated BTBR WT and BTBR ob/ob mice. Daily urinary creatinine was elevated in BTBR ob/ob mice (0.565±0.06 vs 0.989±0.2 mg/24 h, Po0.05, BTBR WT vs BTBR ob/ob), and CP treatment had no effect on either BTBR WT (0.565±0.06 vs 0.445±0.059 mg/24 h, P ¼ 0.1501, BTBR WT vs BTBR WT þ CP) or BTBR ob/ob mice (0.989 ± 0.2 vs 1.050 ± 0.1 mg/24 h, P ¼ 0.7756, BTBR ob/ob vs BTBR ob/ob þ CP). Surprisingly, CP-treated BTBR WT mice had pronounced albuminuria (Figures 4b and c ), despite having normal urine flow (Figure 4a ). BTBR ob/ob mice were polyuric (Figure 4a ), albuminuric (Figures 4b and c) , and glycosuric, measured as the % fractional excretion of glucose (0.49±0.04 vs 2.71±0.73%, BTBR WT vs BTBR ob/ob, Po0.01). In BTBR ob/ob mice, CP had an antidiuretic effect (Figure 4a ), and abolished glycosuria (2.71 ± 0.73 vs 0.80 ± 0.06%, BTBR ob/ob vs BTBR ob/ob þ CP, Po0.001). Despite these improvements, CP treatment had no effect on the albuminuria in BTBR ob/ob mice (Figures 4b and c ).
Isoprostane production is increased in pathologic conditions associated with oxidative stress and is postulated to be a key component in the development and progression of the renal complications of diabetes. [23] [24] [25] [26] [27] [28] We analyzed the urinary isoprostane, 8-epi, production to evaluate the effects of CP. While 8-epi excretion was elevated in BTBR ob/ob mice, it was, similar to albuminuria, also elevated in CP-treated BTBR WT mice. However, CP had no effect on 8-epi excretion in the BTBR ob/ob mice (Figure 4d ). 
Renal Histology
To characterize the effects of CP on the renal histopathology, we analyzed kidney-TL ratio, glomerular structure, macrophage accumulation, and podocyte content in both BTBR WT and BTBR ob/ob mice. Kidney weight was increased in BTBR ob/ob mice, consistent with previous observations (Hudkins et al; 17 Table 1 ) and treatment with CP significantly decreased kidney size in both groups. Both treated and untreated BTBR WT mice had normal appearing glomeruli (Figures 5a and b ) and glomerular volume (Figure 5i ), whereas the comparable appearance of untreated BTBR ob/ob mice show mesangiolysis, increased matrix deposition, and distinct capillary ballooning (Figure 5c ), accompanied by glomerular volume expansion (Figure 5i ) and macrophage accumulation (Figures 5g and k) . Analysis of glomerular p57positive cells in CP-treated and -untreated BTBR ob/ob mice demonstrated that CP treatment had no effect on glomerular podocyte content (5.35 ± 0.09 vs 5.49 ± 0.08, BTBR ob/ob vs BTBR ob/ob þ CP, P ¼ 0.2258).
Renal Gene Expression and Mitochondrial DNA analysis
The metabolic burden of diabetes has been associated with mitochondrial dysfunction. We analyzed mRNA expression of genes associated with b-oxidation, namely acox1, cpt1a, and cpt2, and genes associated with mitochondrial function and biogenesis, namely uncoupling protein 2 (ucp2) and sirtuin 1 (sirt1), 29, 30 from the renal cortex of treated and untreated BTBR WT and BTBR ob/ob mice. Unlike the liver, there were no changes in the expression of acox1, cpt1a, and cpt2 (Figures 6a-c) in BTBR ob/ob kidneys. However, ucp2
and sirt1 expression were increased (Figures 6d and e ). CP treatment increased acox1 and ucp2 in BTBR WT mice (Figures 6a and d) , but did not have any effects on acox1, cpt1a, and cpt2 expression in the BTBR ob/ob mice. However, CP treatment abolished the elevated sirt1 expression in the BTBR ob/ob mice (Figure 6d ). The tricarboxylic acid cycle and b-oxidation pathway are two major enzymatic pathways within the mitochondria, serving not only as sources of energy but also of reactive oxygen species (ROS) production. When levels of ROS exceed mitochondrial antioxidant capacity, the resultant oxidative stress can damage mtDNA and result in the creation of base pair mutations and deletion of mutated base pairs. 31 The Random Mutation and Deletion Capture Assay permit us a highly sensitive method of detection of these changes in mtDNA in the renal cortex of CP-treated WT and ob/ob mice. Mutation frequency was determined at TaqI restriction site. 31 Analysis of mtDNA showed no differences in point mutation frequency (mutations per base pair (m.b.p.)) in the renal cortex of BTBR ob/ob mice compared with BTBR WT controls (3.5±0.40 Â 10 À 6 vs 15.9±11.9 Â 10 À 6 m.b.p., BTBR WT vs BTBR ob/ob, P ¼ 0.343). CP had no effect on point mutations in either BTBR WT (3.5±0.4 Â 10 À 6 vs 10.6 ± 4.9 Â 10 À 6 m.b.p., BTBR WT vs BTBR WT þ CP, P ¼ 0.114) or in BTBR ob/ob (10.6 ± 4.92 Â 10 À 6 vs 4.4 ± 0.4 m.p.b., BTBR ob/ob vs BTBR ob/ob þ CP, P ¼ 0.5530). No differences were observed in either total mtDNA copy number in treated vs untreated BTBR WT (1518±142 vs 1182±142, BTBR WT vs BTBR WT þ CP, P ¼ 0.200) or BTBR ob/ob mice (1351±116 vs 1720±92 
DISCUSSION
The fibrate class of PPARa agonists has been used safely to lower TG, increase HDL-C, and improve cardiovascular outcomes in diabetic patients, 12, 13 mainly by activating the expression of genes involved in lipid homeostasis. 5 Data from the FIELD and ACCORD studies suggested beneficial effects of fibrates in DN, with fenofibrate usage associated with attenuation of microalbuminuria. 12 In this study, we tested the benefits of a prototypic member of a class of novel PPARa agonists in a well-characterized murine model of advanced DN, potentially delineating intrarenal and extrarenal mechanisms for its anticipated benefits. While PPARa agonists have been shown to be efficacious in ameliorating renal injury in animal models with mild or moderate structural changes of DN, it remains unknown whether they can provide substantial benefit in more advanced disease. Our studies demonstrate beneficial effects of CP treatment for the overall diabetic state, but they are somewhat disappointing in that they did not significantly ameliorate DN within the time frame of CP intervention.
Our studies extend those previously reported for the BTBR ob/ob mouse in demonstrating that the characteristic presence of hyperglycemia, IR, hypertriglyceridemia, inflammation, and DN in this model. Additional novel findings were increases in circulating NEFA and IL-6, and decreases in adiponectin, which further characterize this strain as a comprehensive model of T2DM and obesity. In the liver, genes associated with b-oxidation were increased, along with PPARg expression. We also observed that, in general, CP had a growth-retarding influence in both BTBR WT and BTBR ob/ob mice. This decrease in growth was not due to a lack of nutrition, as food intake (as measured by g per cage) actually increased in BTBR WT mice (unpublished observation). CP had no effect on food intake in BTBR ob/ob mice, an unsurprising observation given the role of the ob gene in the control of satiety. The CP-induced decreases in growth in these mice are most likely due to general catabolic effects of PPARa activation, 20 and by studies demonstrating PPARa expression in growth plate chondrocytes, whose activation closes the growth plate, hence inhibiting long bone growth. 32 CP treatment of BTBR ob/ob mice attenuated BW, hyperglycemia, hypertriglyceridemia, systemic inflammation, and IR. However, CP had no effect on plasma HDL-C, while increasing total cholesterol levels. Piperidine-derived PPARa agonists have anti-inflammatory properties, in part, by decreasing proinflammatory cytokine expression and release. 20 We analyzed the effect of CP on serum adiponectin, IL-6, and TNF-a, cytokines used as indicators of systemic inflammation, observing that elevated plasma IL-6 levels in BTBR ob/ob mice were abolished by CP, without any effect on adiponectin. CP and other piperidine-derived PPARa agonists have demonstrated effects consistent with the activation of PPARa. 20, 21 While we do not have any direct evidence of CP directly activating PPARa in our study, the robust increases in the expression of hepatic genes associated with b-oxidation in CP-treated mice gives strong evidence that PPARa is indeed activated. This is supported by the decreases in inflammatory markers and the reduction in plasma glucose, as CP-activated PPARa seems to have antiinflammatory role, mainly by decreasing acute-phase response and gluconeogenic enzymes. 20 Studies of the effects of PPARa agonists in rodent models of diabetes and DN have shown varying degrees of benefit. For example, type 1 diabetic mice lacking the PPARa gene have diminished kidney function, increased glomerular damage, and accelerated DN, indicating a protective role of PPARa. 33 Additionally, fenofibrate treatment in Zucker diabetic fatty rats attenuated renal inflammation and tubular injury, evidenced by decreases in renal expression of monocyte chemotactic protein-1 and interstitial macrophage infiltration, ameliorating diabetes-associated kidney damage. 34 Improvement of kidney damage and function was most striking in fenofibrate-treated C57 BLKS db/db mice. 35 Similar to our study, treatment of obese and diabetic mice caused hypoglycemia, amelioration of IR, and attenuation of BW. While the increases in plasma ALT/AST levels and increases in total cholesterol appear to be confounders in this study, it is important to note that fenofibrate also caused hepatomegaly and increases in total cholesterol levels that were not accounted for with the changes in HDL-C in C57 BLKS db/db mice. 35 In addition, while CP increased ALT/AST in both BTBR WT and BTBR ob/ob mice, it did not cause any changes in glomerular histopathology in the BTBR WT mice. CP also decreased CK levels in BTBR ob/ob mice, indicating a systemic benefit, leading us to conclude that the increases in liver function parameters is something unique to rodents and not related to renal damage. This is supported by the observation that fenofibrate had beneficial effects on the renal function and histopathology associated with T2DM in C57 BLKS db/db mice. We hypothesize that the difference between this study and ours, outside of the obvious ones (treatment and study regimen, leptin receptor-deficient vs leptin-deficient mice), may be because of the persistent hyperinsulinemia present in the BTBR ob/ob mice. Insulin levels measured at the termination of the study (C57 BLKS db/db vs BTBR ob/ob, respectively) were approximately 4-5 Â higher in the BTBR strain, levels that are not significantly affected by CP treatment (despite the improvement of IR). When leptin-deficient (ob) is introduced into the BTBR genetic background strain, the resultant hyperglycemia and IR is more severe than when it is introduced to age-and gendermatched C57BLKS mice. 36 The BTBR strain has genetic deficiencies associated with both pancreatic b-cell function and peripheral IR, [37] [38] [39] variables that were not affected by CP treatment. This chronic and unresolved hyperinsulinemic state, unaffected by systemic and metabolic parameters, may alter numerous signaling pathways associated with DN. Without any modification of this state, amelioration of DN may not be possible. Alternately, the 16-week-old C57 BLKS db/db mouse used by the prior study has only very mild structural changes of DN when compared with the marked changes of the 18-week-old BTBR ob/ob mouse. 16 The advanced structural injuries of the BTBR ob/ob mouse may not be amenable to changes induced by PPARa agonists, despite improvements in diabetes-associated abnormalities.
Isoprostanes as Contributors in the Initiation and Progression of DN
The increased risks for renal disease in diabetes are multifactorial, with ROS being one of the primary drivers of disease progression. [23] [24] [25] ROS can directly damage molecules and cells, and target those that have been irretrievably damaged for degradation, eventually leading to loss of function. In the kidney and depending on cell type, ROS can arise from a number of different mechanisms, such as glycolysis, nitric oxide synthase (NOS) dysfunction, and the activation of the NADPH oxidases. [23] [24] [25] Renal ROS production is balanced by a variety of antioxidant defense systems, (ie, superoxide dismutase (SOD), catalase and thioredoxin, and their accessory proteins) and oxidative balance is integral to normal function. In the diabetic kidney, dysregulation of these pathways result in cell damage, eventually leading to DN. For example, decreased expression of cytosolic and extracellular SOD was observed in mice susceptible to DN, when compared with DN-resistant mice, 40 and eNOS deficiency, perhaps leading to excess oxidative stress, can produce an accelerated nephropathy. 41 Conversely, renal expression of the endogenous inhibitor of thioredoxin, the thioredoxin-interacting protein, was increased in the . Glomerular macrophage accumulation, as analyzed by the macrophage-specific antibody Mac-2 (e-h, k) in BTBR ob/ob mice, compared with BTBR WT (g vs e, respectively). CP treatment has no effect on macrophage content in BTBR WT or BTBR ob/ob glomeruli (e-h). Glomerular volume (i), mesangial matrix deposition (j), and macrophage content (k) in CP-treated BTBR WT (open bars; untreated BTBR WT, n ¼ 9, BTBR WT þ CP, n ¼ 9) and BTBR ob/ob (closed bars; untreated BTBR ob/ob, n ¼ 9, BTBR ob/ob þ CP, n ¼ 9) kidneys were quantified as described in Materials and Methods. Results are shown as means±s.e.m. Statistical analysis was performed using one-way analysis of variance followed by Newman-Keuls post hoc test. *Po0.05 vs BTBR WT; # Po0.05 vs BTBR ob/ob. streptozotocin-induced, type 1 diabetes (mRen-2)27 mouse, 42 an increase that was associated with DN. In both models, these changes led to increases in ROS production. We observed elevated ROS production in the glomeruli of BTBR ob/ob mice, 18 and preliminary analyses of these kidneys demonstrated decreased expression of SOD (unpublished observation), indicating that dysregulation of antioxidant balance and resultant oxidative stress is associated with kidney dysfunction. Therefore, CP, despite removing what are considered to be the main systemic drivers of ROS (elevated glucose, lipids, and increased inflammation), by increasing elevated fatty acid oxidation in the BTBR ob/ob kidney, essentially replaces one source of ROS with another. Some of the effects of oxidative stress are mediated by the ROSmediated modifications of arachidonic acid (AA). 27, 28, 43 These urinary metabolites of AA, such as the F 2isoprostanes (F 2 -Isops), have been used in numerous studies as an indicator of oxidative stress. 28 The best-characterized member of the F 2 -Isops, 8-epi, is also purported to be a direct modulator of renal function, acting via the thromboxane A 2 receptor (TP), 44 activation of which can lead to NOS uncoupling, renal hyperfiltration, albuminuria, and glomerular damage. [44] [45] [46] In fact, the selective TP receptor antagonist, S1886 (Terutobran), has been shown to attenuate renal damage in a rodent models of hypertension, 47 and type 1 48 and type 2 diabetes. 49 In this study, we show elevated renal excretion of 8-epi, but not 8OH-dG, a marker of oxidative-induced DNA damage and a putative risk factor for diabetes. 50, 51 The increase in 8-epi can activate glomerular TP, and via sensitization of the tubuloglomerular feedback mechanism, increase glomerular filtration pressure and albumin excretion. 44 The fact that CP increased 8-epi and albuminuria, without having any effects on urinary creatinine, in lean, non-diabetic control mice, without any changes in glomerular histology, supports the hypothesis that it is a direct effect of 8-epi on the glomerular filtration that results in albuminuria. Whether the production and release of renal isoprostanes in this model is involved in the initiation and progression of DN remains to be elucidated. Another possible explanation underlying the albuminuric effects CP in BTBR WT mice involves the role of PPARa in the regulation of renal RAAS and intrarenal hemodynamics. It is possible that, in the kidney, PPARa may serve as a mediator of the RAAS. In the Tsukuba hypertensive mouse, a model of angiotensin II-dependent hypertension, administration of fenofibrate, contrary to most observations on the effect of fibrates in models of hypertension, worsened systemic blood pressure. 52 The Tsukuba hypertensive mouse has high plasma renin activity, with elevated levels of angiotensin II and aldosterone. This observation is not consistent with a significant number of studies demonstrating an antihypertensive effect of PPARa activation. [53] [54] [55] We have observed that BTBR ob/ob mice were hypotensive when compared with their their WT counterparts, 18 which can be attributed to the lack of leptin. 56 Does CP increase systemic or intrarenal pressure in the BTBR strain? It is possible that the activation with PPARa with CP can modulate vascular tone in renal arterioles and influence filtration pressure, leading to increase in albumin excretion. Additional studies either using TP receptor antagonists or by isolating and analyzing a possible RAAS-PPARa axis in the BTBR strain will be required to provide definitive answers to these questions.
In summary, treatment with CP had many beneficial effects in the BTBR ob/ob mouse, reducing plasma TGs and many of the hallmarks of type 2 diabetes. Despite the improvements in metabolic parameters, CP did not ameliorate nephropathy, albuminuria, glomerular hypertrophy, mesangial matrix expansion, glomerular macrophage content, podocyte loss, and renal ROS production. However, the failure of CP on preventing the development of DN, while disappointing, can gives us further insight on factors that may mediate the renal complication of diabetes. Based on our results, we propose that dysfunctional renal antioxidant mechanisms, one perhaps regulated by insulin-dependent pathways, result in elevations in the production of renal F 2 -Isops. Additionally, the production of these metabolites may serve as an important contributor to the renal complication of diabetes in the BTBR ob/ob mouse, and therapies targeted to the treatment of DN should focus on decreasing either the production or the action of renal F 2 -Isops. 
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